Immortalized B-Cell Discovery of SDCBP-Targeted Ovarian Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for ovarian endometriosis and associated cancers are lacking, and the standard of care for ovarian cancer involves aggressive surgery and chemotherapy with high relapse rates, necessitating the development of novel therapeutics.
Innovation Solution
Development of anti-syndecan binding protein (SDCBP) binding molecules, such as antibodies and nanobodies, targeting specific complementary determining regions (CDRs) to treat ovarian cancer and endometriosis, including clear cell carcinoma, endometrioid carcinoma, and high-grade serous ovarian carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aggressive cytoreductive surgery and chemotherapy are used to treat ovarian cancer, then initial response rate is improved (more than 80% response), but relapse rate increases (majority of patients ultimately relapse)
Solution Approach 1:
The patent identifies and targets SDCBP as a therapeutic antigen before chemotherapy resistance develops. By using anti-SDCBP binding molecules as a preventive or early intervention therapy, the treatment aims to eliminate tumor cells before they develop resistance to conventional chemotherapy, thereby extending the duration of remission and reducing relapse rates.
Solution Approach 2:
The patent shifts the therapeutic parameter from non-specific chemotherapy to specific antigen-targeted immunotherapy. This parameter change involves targeting SDCBP, a specific protein expressed on ovarian cancer cells, thereby providing a more precise and potentially durable treatment approach that addresses the relapse problem.
2Quantity of substance
If conventional chemotherapy is used to treat ovarian cancer, then initial tumor reduction is achieved, but chemotherapy resistance develops
Solution Approach 1:
The patent extracts and isolates the specific therapeutic target (SDCBP antigen) from the complex tumor environment. By focusing on this single, well-defined antigen that is specifically expressed on ovarian cancer cells, the treatment avoids the non-specificity of chemotherapy and the subsequent development of resistance, thereby maintaining treatment effectiveness.
Solution Approach 2:
The patent introduces anti-SDCBP binding molecules as an intermediary between the immune system and ovarian cancer cells. These binding molecules specifically recognize and bind to SDCBP on tumor cells, facilitating immune-mediated destruction of cancer cells while sparing normal cells, thus maintaining long-term treatment effectiveness without resistance development.
3Productivity
If standard chemotherapy protocols are applied to ovarian cancer, then initial response is achieved, but survival rate remains limited (5-year survival 49.1%, drops to 30.1% at advanced stage)
Solution Approach 1:
The patent employs SDCBP-targeted immunotherapy as a preliminary or adjuvant treatment to conventional chemotherapy. By eliminating SDCBP-positive tumor cells early in the disease course or at relapse, this approach aims to extend overall survival and improve the 5-year survival rate, particularly for advanced-stage patients who have limited options.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-SDCBP binding molecules effectively inhibit tumor growth and metastasis in ovarian cancer models, offering a potential alternative to existing treatments with improved patient outcomes.
Implementation Method 1
anti-syndecan binding protein (SDCBP) binding molecules, such as antibodies and nanobodies, targeting specific complementary determining regions (CDRs)
Data Source
AI summary
Disclosed are anti-syndecan binding protein (SDCBP) binding molecules and methods for using anti-SDCBP in the treatment of cancer, including, but not limited to endometriosis or ovarian cancer.